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All FDA-approved antipsychotic drugs (APDs) target primarily dopamine D2 or serotonin (5-HT2A) receptors, or both; however, these
medications are not universally effective, they may produce undesirable side effects, and provide only partial amelioration of negative and
cognitive symptoms. The heterogeneity of pharmacological responses in schizophrenic patients suggests that additional drug targets may be
effective in improving aspects of this syndrome. Recent evidence suggests that 5-HT2C receptors may be a promising target for
schizophrenia since their activation reduces mesolimbic nigrostriatal dopamine release (which conveys antipsychotic action), they are
expressed almost exclusively in CNS, and have weight-loss-promoting capabilities. A difficulty in developing 5-HT2C agonists is that most
ligands also possess 5-HT2B and/or 5-HT2A activities. We have developed selective 5-HT2C ligands and herein describe their preclinical
effectiveness for treating schizophrenia-like behaviors. JJ-3-45, JJ-3-42, and JJ-5-34 reduced amphetamine-stimulated hyperlocomotion,
restored amphetamine-disrupted prepulse inhibition, improved social behavior, and novel object recognition memory in NMDA receptor
hypofunctioning NR1-knockdown mice, and were essentially devoid of catalepsy. However, they decreased motivation in a breakpoint
assay and did not promote reversal learning in MK-801-treated mice. Somewhat similar effects were observed with lorcaserin, a 5-HT2C
agonist with potent 5-HT2B and 5-HT2A agonist activities, which is approved for treating obesity. Microdialysis studies revealed that both
JJ-3-42 and lorcaserin reduced dopamine efflux in the infralimbic cortex, while only JJ-3-42 decreased it in striatum. Collectively, these
results provide additional evidence that 5-HT2C receptors are suitable drug targets with fewer side effects, greater therapeutic selectivity,
and enhanced efficacy for treating schizophrenia and related disorders than current APDs.
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INTRODUCTION
Atypical antipsychotic drugs (APDs) are the first choice
for treating schizophrenia (SZ) and they act primarily
through blockade or partial antagonism of dopamine (DA)
D2 receptors and inverse agonism at serotonin 2A (5-HT2A)
receptors, together with activities at other DA and 5-HT
receptors (Meltzer et al, 1989; Roth et al, 2004). Psychotic
disorders include SZ, schizoaffective disorder, bipolar
disorder, major depression, and various neurological condi-
tions (Arciniegas et al, 2001; Wigman et al, 2012; Landqvist-
Waldö et al, 2015). The limited efficacy of atypical APDs for
treating negative symptoms and cognitive impairment in SZ,
and the role of N-methyl-D-aspartate receptor (NMDAR)
antagonists to induce cognitive deficiency in man and
laboratory animals implicates glutamate (Glu) and
γ-aminobutyric acid (GABA) receptors in some aspects of
SZ (López-Gil et al, 2010). It is now established that atypical
APDs are superior to selective D2 antagonists for improving
cognitive function in SZ (Désaméricq et al, 2014; Meltzer,
2015), while having modest effects on negative symptoms
(Leucht et al, 1999; Miyamoto et al, 2005).
There is some evidence that 5-HT2C agonists have
antipsychotic efficacy (Marquis et al, 2007). This receptor
interacts with Gq/11 protein to activate phospholipase Cβ,
leading to intracellular calcium release (Conn et al, 1986;
McCorvy and Roth, 2015). In rodents, 5-HT2C mRNA is
present in dorsal and ventral striatum and is coexpressed
primarily in substantia nigra and ventral tegmental area
(VTA) neurons containing glutamic acid decarboxylase
mRNA (Bubar et al, 2011; Eberle-Wang et al, 1997), where
the 5-HT2C receptor may indirectly inhibit DA neurons
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through GABA interneuronal activation. Neurochemical and
electrophysiological studies confirm this point, as a 5-HT2C
inverse agonist increases firing in VTA and substantia nigra,
enhances VTA bursting activity, and leads to DA release in
the nucleus accumbens (NAc) and striatum—with more
pronounced effects on DA mesolimbic neurons (Gobert et al,
2000). Intrastriatal administration of this inverse agonist
increases DA release in the lateral striatum (Alex et al, 2005).
Conversely, the 5-HT2C agonist Ro-60-0175 decreases DA
release in the NAc and striatum (Gobert et al, 2000). This
agonist blocks cocaine-induced open field hyperactivity and
the selective 5-HT2C antagonist SB 242 084 reverses this
effect (Grottick et al, 2000). However, Ro-60-0175 fails to
alter cocaine-induced DA release and a 5-HT2C inverse
agonist does not influence amphetamine (AMPH)-stimu-
lated DA release in NAc or striatum of halothane-
anesthetized rats (Porras et al, 2002; Navailles et al, 2004).
Hence, the effects of 5-HT2C agonists may involve striatal
non-dopaminergic postsynaptic mechanisms. Further evi-
dence for a modulatory role of 5-HT2C receptors on DA
function derives from Htr2c disruption, resulting in elevated
DA release in dorsal striatum and enhanced AMPH-induced
stereotypies in mice (Abdallah et al, 2009). In humans, the
HTR2c polymorphism Cys23Ser is associated with augmen-
ted striatal DA release during pain stress (Mickey et al, 2012).
Since non-medicated SZ patients may have elevated DA
synthesis and release in caudate (Kegeles et al, 2010), 5-HT2C
ligands may represent a new generation of APDs that
modulate dopaminergic neurotransmission in the striatum.
Recently, we have published the synthesis and initial
behavioral characterization of novel 5-HT2C agonists with
promising APD properties in mouse models of SZ (Cheng
et al, 2015, 2016). SZ is a neurodevelopmental disorder
characterized by positive and negative symptoms, and
cognitive impairment. There is an urgent need to control
APD-induced side effects, such as neuroleptic malignant
syndrome, psychomotor retardation, weight gain, and blood
and bone marrow complications. Notably, novel 5-HT2C
ligands show promise in treating obesity (Smith et al, 2010)
and improving glycemic control in type 2 diabetes patients
(O'Neil et al, 2012). Preclinical studies suggest possible
procognitive actions of 5-HT2C agonists in novel object
recognition memory (NORM) (Cheng et al, 2016).
The present study examined effects of three novel
compounds with selective 5-HT2C agonism in pharmacolo-
gical and genetic models of SZ. For positive symptoms,
AMPH-induced hyperactivity and disruption of prepulse
inhibition (PPI) were used. For negative symptoms, we
focused on motivational impairment and avolition using a
breakpoint assay. We also used the sociability test with the
NMDAR hypofunctioning NR1-knockdown (NR1-KD) mice
(Mohn et al, 1999; Milenkovic et al, 2014; Park et al, 2016).
For cognition we included NORM and a visual discrimina-
tion reversal test. For possible extrapyramidal side effects, we
used the horizontal bar test for catalepsy. Finally, we
measured the effects of one of the compounds on
extracellular levels of neurotransmitters in the infralimbic
cortex and striatum of mice.
MATERIALS AND METHODS
Detailed descriptions of the methods and procedures can be
found in the Supplementary Information.
Animals
Adult male and female C57BL/6J and female C3H/HeJ mice
were purchased (Jackson Laboratories, Bar Harbor, ME),
whereas wild-type (WT) and NR1-KD mice were bred and
maintained as described (Park et al, 2016). Mice were housed
3–5 per cage on a 14 : 10 h light : dark cycle (Duke: lights on
0700 h) for behavioral studies and on a 12 : 12 h light : dark
cycle (Northwestern: lights on 0500 h) for microdialysis
experiments, with food and water provided ad libitum.
Six cohorts were used: cohort 1, open field activity and
PPI; cohort 2, motivation; cohort 3, sociability and NORM;
cohort 4, visual discrimination learning and reversal; cohort
5, catalepsy; and cohort 6, microdialysis. At least 10 days
were interposed between tests within any cohort. All
experiments were conducted with approved protocols from
the Duke and Northwestern Universities Institutional
Animal Care and Use Committees.
Drugs
The lorcaserin (Selleckchem LLC, Houston, TX), AMPH
(Sigma-Aldrich, St Louis MO), MK-801 (Sigma-Aldrich),
and JJ-3-45, JJ-3-42, and JJ-5-34 were reconstituted in
sterile 0.9% saline. Clozapine (Sigma-Aldrich) was dissolved
in 0.2% glacial acetic acid with saline, whereas halo-
peridol (Sigma-Aldrich) was dissolved to a final concen-
tration of 3% dimethylsulfoxide. All treatments were
administered (intraperitoneally) in 5 ml/kg volume, except
as noted.
Open Field Activity
C57BL/6J mice were injected with vehicle or different
doses of the 5-HT2C-selective compounds or lorcaserin,
placed into the open field (Omnitech, Columbus, OH) for
15 min, removed and injected with vehicle or 3 mg/kg
AMPH, and immediately returned to the apparatus for
105 min. Activity was monitored as cumulative distance
traveled.
Prepulse Inhibition
C57BL/6J mice were administered vehicle, different doses of
the 5-HT2C-selective compounds, or lorcaserin in their home
cage. Ten minutes later, animals were given vehicle or
3 mg/kg AMPH and acclimated to a 65 dB white-noise
background in the PPI apparatus (San Diego Instruments,
San Diego, CA). Five minutes later, mice were presented with
combinations of startle (120 dB), prepulse-pulse (4, 8, and
12 dB over the 65 dB background followed by 120 dB), and
null trials over 25 min (Park et al, 2016). Activity was
recorded during all trials. The data were presented as percent
PPI= (1− (prepulse trials/startle-only trials)) × *100, and as
startle and null activities.
Breakpoint as an Index of Motivation
Throughout the experiment mice were food restricted to 85–
90% of baseline body weight and housed 4/cage. Mice were
trained initially on a continuous reinforcement schedule with
condensed milk as a reward. Subsequently, animals were
trained on a progressive ratio schedule where the number of
bar presses required to earn the reward doubled. Once
performance was stable, mice were injected with vehicle, the
JJ compounds, or lorcaserin and tested. Breakpoint (highest
ratio completed) was recorded.
Sociability
There were three phases to this test: identical non-social
(control), a social and non-social (social affiliation), and a
novel and familiar social pairing (social preference). Female
C3H/HeJ mice were used as partners with WT and NR1-KD
tester mice. The tester NR1 mice were injected with vehicle,
0.5 mg/kg clozapine (positive control), or different doses of
the 5-HT2C-selective compounds or lorcaserin. Ten minutes
later, individual tester NR1 mice were evaluated sequentially
in 10 min tests for responses to two identical non-social
stimuli (empty wire-mesh cages), to novel social (C3H/HeJ
mouse) and non-social stimuli, and to novel social (C3H/HeJ
mouse) and now familiar social (previous C3H/HeJ mouse)
stimuli. The duration of stimulus contacts was monitored.
Preference scores ((time spent with one stimulus− time
spent with the other stimulus)/total time spent exploring
both stimuli) were calculated where positive scores indicated
a preference for the non-social stimulus in the first test, for
the social stimulus in the second test, and for the novel social
stimulus in the third test.
Novel Object Recognition Memory
Before training, WT and NR1-KD mice were administered
the vehicle or different doses of the 5-HT2C-selective
compounds or lorcaserin, and 30 min later, they were
presented with identical object pairs for 5 min. The next
day mice were administered the same treatments and were
tested after 30 min. Here, one of the now familiar objects was
replaced with a novel object and the mice were tested over
5 min. The duration of object contracts was calculated as a
control. Recognition scores ((time spent with novel object−
time spent with familiar object)/total time with both objects)
were calculated where positive scores signified novel object
preference, negative scores indicated familiar object pre-
ference, and scores approaching ‘zero’ denoted no object
preference.
Reversal of Visual Discrimination Learning
Since behavioral responses across tests were similar for the
three JJ compounds, we only evaluated JJ-3-45 and selected
the 2 mg/kg dose because this was the highest dose that did
not disrupt the visual discrimination and was close to the
optimal dose for NORM. Touchscreens were used to display
two separate images for visual discrimination and reversal
(Med Associates).
Throughout the experiment mice were food-restricted to
85–90% of baseline body weight and housed 3–5 mice per
cage. At training mice were taught to nose poke at white
rectangles to receive a condensed milk (Kroger) reward.
Subsequently, mice were trained on a simultaneous dis-
crimination where one of two stimuli was reinforced. Upon
reaching a criterion of 80% correct responses, the mouse was
given MK-801 or JJ-3-45 to determine which doses would
not perturb its visual discrimination performance. Subse-
quently, mice were assigned to vehicle, MK-801, and MK-801
plus JJ-3-45 groups and these treatments were chronically
administered. The mice were tested in the visual discrimina-
tion for two additional sessions and then the reward
contingencies were reversed. Responses were scored as the
number of correct trials, number of errors, and percent
correct ((correct/total trials) × 100).
Catalepsy
Baseline responses were recorded and then separate groups
of C57BL/6J mice were injected with haloperidol, different
doses of the three JJ compounds, or lorcaserin. Mice were
tested 60 min later for catalepsy. The latency for a mouse to
remove its paws from the bar was recorded as an index of
catalepsy with a maximum time of 90 s.
Microdialysis Procedure and Analyses of
Neurotransmitters
C57BL/6J males were housed in groups of 3–5 per cage until
surgery; afterwards, they were housed individually. Mice
were anesthetized with 1.5% isoflurane (Isothesia; Butler-
Schein, Dublin, OH) and cannulated with dummy probes in
the infralimbic cortex and ventral striatum. Two days later,
microdialysis probes were inserted on the morning of the
experiment with perfusion at 1 μl/min. Two hours later,
microdialysis samples were collected every 30 min. After
90 min, mice were injected with vehicle, 10 mg/kg JJ-3-42, or
1 mg/kg lorcaserin and samples were collected over another
180 min. Parenthetically, the doses for JJ-3–42 and lorcaserin
were based on the open field experiment. Samples
were submitted to mass spectrometry for acetylcholine
(ACh), DA, norepinephrine, 3,4-dihydroxyphenylacetic acid
(DOPAC); homovanillic acid (HVA), 5-HT, 5-hydroxyind-
oleacetic acid (5-HIAA), Glu, and GABA. Baseline was
designated as 100% and subsequent neurochemical levels
were expressed as percent baseline.
Statistical Analyses
The data were presented as means and standard errors of the
mean. One-, two-way, or repeated-measures ANOVA
(RMANOVA) were used with Dunnett or Bonferroni post
hoc analyses. Owing to variability in the neurochemistry,
some data were analyzed by Kruskal–Wallis, followed by
Mann–Whitney tests. A Po0.05 was considered significant.
RESULTS
AMPH-Stimulated Hyperlocomotion in C57BL/6J Mice
AMPH-stimulated hyperlocomotion is used as a model
of hyperdopaminergia in rodents and APDs reduce it
(Geyer and Moghaddam, 2002). JJ-3-45, JJ-3-42, JJ-5-34, or
lorcaserin were injected and baseline activity was assessed
over the first 15 min. Relative to vehicle, basal locomotion
was attenuated by 30 mg/kg JJ-3-45 (Po0.001; Figure 1a)
and 5mg/kg JJ-3-42 (Po0.042; Figure 1b), but it was
increased with 0.25 mg/kg lorcaserin compared with all
other groups (P-valueso0.014; Figure 1d).
After baseline assessment, vehicle or AMPH (3 mg/kg,
intaperitoneally) was injected and mice were returned to the
open field for 105 min. The 20 and 30 mg/kg JJ-3-45
decreased the AMPH-induced hyperactivity (P-value-
so0.045), such that responses to the highest dose were
similar to the vehicle control (Figure 1e). Similarly, 10 and
20 mg/kg JJ-3-42 suppressed hyperlocomotion (P-values
o0.050) to levels statistically indistinguishable from vehicle
controls (Figure 1f). By comparison, only 20 mg/kg JJ-5-34
reduced AMPH-induced hyperlocomotion (Po0.001) to
the vehicle control (Figure 1g). Thus, all novel 5-HT2C
compounds antagonized the AMPH-stimulated response. By
contrast, lorcaserin failed to inhibit the AMPH-stimulated
effect until the highest dose was used (Po0.001; Figure 1h).
AMPH-Disrupted PPI in C57BL/6J Mice
PPI is reduced in SZ and APDs can normalize AMPH-
disrupted PPI in rodents (Krystal et al, 1999; Geyer and
Moghaddam, 2002). JJ-3-45, JJ-3-42, JJ-5-34, or lorcaserin
were administered, 10 min later the vehicle or AMPH
(3 mg/kg, i.p.) were given, and the mice were tested after
Figure 1 All three JJ compounds and lorcaserin reduced the 3 mg/kg amphetamine-stimulated hyperlocomotion in the open field and restored
amphetamine-disrupted prepulse inhibition (PPI) in C57BL/6 mice. (a–d) Open field baseline locomotor activity (0–15 min) in mice administered JJ-3-45, JJ-3-
42, JJ-5-34, or lorcaserin. A one-way analysis of variance (ANOVA) observed a main effect of dose: JJ-3-45 (F(5,81)= 6.740, Po0.001), JJ-3-42
(F(4,75)= 2.604, Po0.042), JJ-5-34 (F(4,62)= 3.511, Po0.012), and lorcaserin (F(4,46)= 6.892, Po0.001). (e–h) Amphetamine-stimulated hyperlocomotion
(105 min) with dose responses for JJ-3-45, JJ-3-42, JJ-5-34, and lorcaserin. A one-way ANOVA noted a main effect of dose: JJ-3-45 (F(5,81)= 14.718,
Po0.001), JJ-3-42 (F(4,75)= 18.232, Po0.001), JJ-5-34 (F(4,62)= 15.448, Po0.001), and lorcaserin (F(4,46)= 9.987, Po0.001). (i–l) Dose responses for JJ-3-
45, JJ-3-42, JJ-5-34, and lorcaserin in PPI. A repeated-measures ANOVA (RMANOVA) within-subjects effects for PPI intensity (F(2,242)= 315.229, Po0.001);
between subjects effects for treatment (F(14,121)= 5.302, Po0.001). Groups: V–V, vehicle–vehicle control; V–A, vehicle–amphetamine. N= 9–31 mice per
compound or drug dose in the open field study and N= 8–15 mice per compound or drug dose in the PPI experiment; *Po0.001, compared with the V–V
control; ^Po0.01, compared with the V–A group.
5 min. AMPH depressed PPI compared with the vehicle
control (Po0.001; Figure 1i–l). All compounds reversed this
disruptive effect as demonstrated with 0.5 mg/kg JJ-3-45; 1, 2,
and 4 mg/kg JJ-3-42 and JJ-5-34; and 0.5 and 1mg/kg
lorcaserin (P-valueso0.006). Startle activity varied with
treatment and this was due to a dose-induced reduction in
responses (Table 1); however, the post hoc tests were not
significant. Null (baseline) activity was significantly en-
hanced with 0.1 and 1mg/kg lorcaserin (P-valueso0.030;
Table 1). Thus, all selective 5-HT2C compounds and
lorcaserin restored the AMPH-disrupted PPI.
Breakpoint as an Index of Motivation in C57BL/6 Mice
Motivation is regulated by mesolimbic dopaminergic neu-
rons and is reduced in SZ (Salamone and Correa, 2012).
Mice were tested on a progressive ratio schedule for food
reinforcement as an index of motivation. They were treated
with the vehicle and different doses of the JJ compounds or
lorcaserin. The 1 and 5mg/kg doses of JJ-3-45 significantly
decreased the breakpoint relative to the vehicle control
(P-valueso0.001) (Figure 2a). Similarly, all doses of JJ-3-42
and JJ-5-34 decreased the breakpoints (P-valueso0.009)
(Figures 2b and c). Lorcaserin depressed lever responding
beginning at 0.5 mg/kg (Po0.029) with higher doses exerting
greater effects on breakpoint (P-valueso0.001) (Figure 2d).
Hence, all JJ compounds and lorcaserin reduced breakpoints
in dose-dependent manner.
Sociability in NR1 Mice
Social withdrawal is a hallmark of SZ and NR1-KD mice
display this response (Mohn et al, 1999). These mutants are
deficient also in sociability and clozapine improves it (Park
et al, 2016). WT and NR1-KD mice were tested in three
phases: a non-social pairing with two identical stimuli, a
pairing with social and non-social stimuli (social affiliation),
and a pairing with the now familiar and a novel social
stimulus (social preference). As a control, the duration of
stimulus contacts was examined and no significant differ-
ences were observed among groups across test phases
(Table 2)—indicating that any deficiencies in social behavior
cannot be attributed to a failure to interact with the non-
social/social stimuli. During the non-social pairing, no group
showed any preference for one over the other identical
stimulus (Figures 2e and f). By comparison, vehicle-treated
WT mice preferred the novel social stimulus in the social
affiliation test relative to NR1-KD mice—which showed no
preference for either stimulus (Po0.001). Within genotype
analyses revealed clozapine decreased WT performance
compared with vehicle (P= 0.010) (Figure 2e), whereas it
augmented NR1-KD responses (P= 0.001) (Figure 2f). Re-
lative to vehicle, there was a tendency for 0.5 mg/kg JJ-3-45
(P= 0.060) to reduce WT social affiliation, whereas it was
increased in mutants given 0.5 mg/kg JJ-3-45 or 1 mg/kg
JJ-5-34 as well as with 0.5 or 1 mg/kg JJ-3-42 or lorcaserin
(P-valueso0.006). In NR1-KD mice a dose-dependent
increase in social affiliation was observed with JJ-5-34
(P= 0.008). Analyses of responses between genotypes
demonstrated that social affiliation was higher in WT than
NR1-KD mice at both doses of JJ-5-34 (P-valueso0.042).



























































































































































































































































































































































































treatment conditions restored NR1-KD social affiliation to
that of the WT vehicle controls.
In the social preference test, vehicle-treated WT mice
preferred the novel over familiar social stimulus, whereas
mutants displayed no preference for either stimulus
(Po0.001) (Figures 2e and f). The within genotype
comparisons revealed that relative to vehicle, clozapine
decreased WT performance (P= 0.001) (Figure 2e) with a
tendency for it to facilitate social preference in NR1-KD mice
(P= 0.064) (Figure 2f). Compared with vehicle, social
preference in WT controls was depressed with 1 mg/kg
JJ-3-45 or JJ-3-42 as well as with 0.5 or 1 mg/kg JJ-5-34 and
lorcaserin (P-valueso0.024). In contrast, this behavior was
increased in mutants with 0.5 mg/kg JJ-3-45 or JJ-3-42 or
with 1 mg/kg JJ-5-34 and lorcaserin (P-valueso0.050). A
dose-dependent decrease in social preference was noted
with JJ-3-42 (P= 0.043) in WT mice (Figure 2e). Impor-
tantly, only 0.5 mg/kg JJ-3-42 restored social preference in
NR1-KD mice to that of the WT vehicle controls (Figure 2e
and f).
In summary, vehicle-treated NR1-KD mice were signifi-
cantly impaired in both social affiliation and social
preference relative to WT vehicle controls. However, all
three JJ compounds and lorcaserin improved both social
behaviors in mutants and decreased them in WT mice.
Notably, only 0.5 mg/kg JJ-5-34 failed to restore social
affiliation in NR1-KD mice to that of the WT vehicle
controls. By comparison, only 0.5 mg/kg JJ-3-42 normalized
social preference in mutants.
NORM in NR1 Mice
NORM examines recognition memory and general mnemo-
nic function (Ennaceur and Delacour, 1988), and NR1-KD
mice are deficient in NORM (Park et al, 2016). During
training, WT and NR1-KD mice demonstrated no object
preference between the two identical objects regardless of
drug-dose assignment (Figure 3a and b). A comparison of
preference scores between training and testing revealed that
at testing WT mice failed to prefer the novel object when
administered 5 mg/kg JJ-5-34, whereas NR1-KD animals
were deficient when given the vehicle, 1 or 10 mg/kg JJ-3-42,
5 mg/kg JJ-5-34, or 0.5 mg/kg lorcaserin. Analyses of
responses within genotype found that in WT mice all
treatments—except 10 mg/kg JJ-3-42 and 1mg/kg JJ-5-34—
reduced NORM below that of the vehicle control
(P-valueso0.012). In contrast, in mutants 5 mg/kg JJ-3-42,
as well as both doses of JJ-3-45, JJ-5-34, and lorcaserin
Figure 2 The JJ compounds and lorcaserin decreased lever pressing under a progressive ratio schedule for food reinforcement in C57BL/6 mice, but
increased social behavior in NR1-knockdown (NR1-KD) mice. (a–d) Dose–responses for JJ-3-45, JJ-3-42, JJ-5-34, and lorcaserin are shown as breakpoints for
assessment of motivation. A repeated-measures analysis of variance (RMANOVA) for JJ-3-45 within-subjects effect of session (F(1,39)= 31.395, Po0.001);
session by dose interaction (F(3,39)= 4.898, Po0.01). A RMANOVA for JJ-3-42 within-subjects effect of session (F(1,42)= 121.664, Po0.001); session by
dose interaction (F(3,42)= 4.103, Po0.012). A RMANOVA for JJ-5-34 within-subjects effect of session (F(1,42)= 50.513, Po0.001). A RMANOVA for
lorcaserin within subjects effect for session (F(1,40)= 57.079, Po0.001), session by dose interaction (F(3,40)= 8.876, Po0.001); between-subjects effect of
treatment (F(3,40)= 2.746, P= 0.055). (e and f) In the sociability test, mice were subjected to three test phases involving pairings of two identical non-social
stimuli, a novel social and a non-social stimulus, and familiar and novel social stimuli. (e) Experiments were conducted with wild-type (WT) mice administered
the vehicle, clozapine (CLZ), or different doses of JJ-3-45, JJ-3-42, JJ-5-34, and lorcaserin. (f) The same treatment conditions were imposed on NR1-KD mice. A
RMANOVA for the vehicle condition: within-subjects effect of test phase (F(2,30)= 17.896, Po0.001), test phase by genotype interaction (F(2,30)= 10.584,
Po0.001); between-subjects effect of genotype (F(1,15)= 54.524, Po0.001). A RMANOVA for the vehicle vs CLZ: within-subjects effect of test phase (F
(2,58)= 37.586, Po0.001), test phase by genotype (F(2,58)= 3.595, P= 0.034), and test phase by genotype by treatment (F(2,58)= 9.284, Po0.001)
interactions; between-subjects effect of genotype (F(1,29)= 20.688, Po0.001), genotype by treatment interaction (F(1,29)= 46.142, Po0.001). A
RMANOVA for the vehicle and CLZ vs JJ-3–45: within-subjects effect of test phase (F(2,118)= 71.591, Po0.001), test phase by treatment (F(6,118)= 2.157,
P= 0.052) and test phase by genotype by treatment (F(6,118)= 3.373, P= 0.004) interactions; between-subjects effects of genotype (F(1,59)= 12.307,
Po0.001) and treatment (F(3,59)= 2.780, P= 0.049), genotype by treatment interaction (F(3,59)= 13.728, Po0.001). A RMANOVA for the vehicle and
CLZ vs JJ-3-42: within-subjects effect of test phase (F(2,118)= 90.784, Po0.001), and the test phase by genotype (F(2,118)= 3.512, P= 0.033), test phase by
treatment (F(6,118)= 3.737, P= 0.002), and test phase by genotype by treatment (F(6,118)= 3.209, P= 0.006) interactions; between-subjects effects of
genotype (F(1,59)= 10.208, P= 0.002) and treatment (F(3,59)= 3.336, P= 0.025), genotype by treatment interaction (F(3,59)= 15.487, Po0.001). A
RMANOVA for the vehicle and CLZ vs JJ-5-34: within-subjects effect of test phase (F(2,118)= 82.860, Po0.001), and the test phase by genotype
(F(2,118)= 3.964, P= 0.022), test phase by treatment (F(6,118)= 2.632, P= 0.020), and test phase by genotype by treatment (F(6,118)= 5.779, Po0.001)
interactions; between-subjects effects of genotype (F(1,59)= 22.227, Po0.001) and treatment (F(3,59)= 3.255, P= 0.028), genotype by treatment interaction
(F(3,59)= 19.790, Po0.001). A RMANOVA for the vehicle and CLZ vs lorcaserin: within-subjects effect of test phase (F(2,114)= 85.422, Po0.001), test
phase by treatment (F(6,114)= 3.208, P= 0.006) and test phase by genotype by treatment (F(6,114)= 7.020, Po0.001) interactions; between-subjects effect
of genotype (F(1,57)= 6.775, P= 0.012), genotype by treatment interaction (F(3,57)= 28.218, Po0.001). N= 8–13 mice per compound or drug dose in the
breakpoint experiment and N= 8–9 mice per genotype per treatment condition in the sociability investigation; *Po0.05, compared with the vehicle group or
the vehicle within genotype; #Po0.05, compared with the WT vehicle control.
Table 2 Duration of Contacts in the Sociability Test with WT and NR1-KD Mice
Veh Clozapine JJ-3-45 JJ-3-42 JJ-5-34 Lorcaserin
mg/kg 0 0.5 0.5 1 0.5 1 0.5 1 0.5 1
Non-social interactiona,b
WT 287.2± 40.8 233.7± 15.6 137.9± 13.2 207.2± 31.7 216.5± 22.7 224.1± 22.3 214.2± 27.0 155.8± 19.0 157.0± 23.9 162.1± 24.1
KDa 194.2± 25.9 205.5± 27.8 191.8± 31.3 216.7± 29.3 197.4± 24.3 245.0± 34 151.7± 27.4 162.7± 32.6 153.9± 12.3 197.3± 23
Social affiliationa,b
WT 285.6± 50.6 255.2± 17.5 162.5± 18.8 213.7± 29.7 189.9± 27.0 220.2± 26.6 231.8± 39.0 182.2± 31.5 190.5± 33.2 172.5± 31.6
KD 207.5± 24.2 223.3± 23.6 196.2± 37.6 208.4± 34.9 174.7± 19.3 229.1± 28.0 143.7± 17.0 146.7± 23.2 205.5± 23.5 235.2± 31.6
Social preferencea,b
WT 260.8± 49.4 197.6± 23.5 146.9± 16.4 205.7± 31.8 224.2± 20.8 189.0± 31.1 231.5± 41.8 133.7± 36.0 204.4± 26.0 198.5± 30.6
KD 150.4± 20.8 172.6± 10.6 196.9± 38.2 159.0± 20.0 189.1± 23.3 225.6± 35.1 177.6± 10.7 185.4± 25.6 203.8± 34.5 222.1± 33.3
Abbreviations: NR1-KD, NR1-knockdown; RMANOVA, repeated-measures analysis of variance; Veh, vehicle; WT, wild type.
aResults are presented as means ±SEM; N= 8–9 mice per drug or compound per dose.
bRMANOVA: only the within-subjects time by treatment interaction was significant (F(18,294)= 1822, P= 0.022).
augmented NORM over that of vehicle (P-valueso0.024).
In comparing responses to the WT vehicle control, 1 mg/kg
JJ-3-45, 5 mg/kg JJ-3-42, and 1 mg/kg JJ-5-34 restored
NORM in the NR1-KD mice. It is noteworthy that 1 mg/kg
JJ-5-34 maintained NORM in WT mice, whereas this
treatment normalized NORM in mutants.
As a control, the duration of object contacts was examined.
Although the object interaction times in RMANOVA failed
to reach statistical significance, the overall duration of
contacts was enhanced in NR1-KD mice during both
training and testing (Table 3). As a consequence, any NORM
deficiencies in mutants cannot be attributed to a failure to
engage the stimulus objects.
Reversal Learning with MK-801 in C57BL/6 Mice
Reversal learning is a test for plasticity or perseverative
responding and it is used in a rodent test battery for SZ-like
behaviors (Bussey et al, 2012). C57BL/6J mice were trained
on a visual discrimination, administered vehicle, MK-801,
or MK-801 plus JJ-3-45 during the latter part of the
discrimination, and tested with reinforcement contingencies
reversed. The preassigned groups did not differ at baseline in
the simple visual discrimination (Figure 3c).
Relative to vehicle controls at reversal, the number of
correct trials was reduced with MK-801 on trials 8 and 10–15
(P-valueso0.048), whereas this metric was suppressed even
further in the MK-801 plus JJ-3-45 group across trials 6–17
(P-valueso0.033) (Figure 3d). Analyses of reversal perfor-
mance according to the number of errors revealed increased
errors in the MK-801 group on trials 3–11 and 13–15
(P-valueso0.051), whereas errors were further potentiated
across all trials in the MK-801 plus JJ-3-45 group
(P-valueso0.002) (Figure 3e). After contingency reversal,
the percentages of correct responses were decreased in
MK-801-treated mice on trials 8, 10–15, and 17 (Pso0.054)
and those in the MK-801 plus JJ-3-45 group were further
depressed across trials 6–17 (P-valueso0.029) (Figure 3f).
Collectively, MK-801 alone and MK-801 plus JJ-3-45
reduced reversal performance below the vehicle control.
Moreover, performance in the MK-801 plus JJ-3-45
group was further suppressed below that of MK-801 alone
at a dose of JJ-3-45 that did not perturb the visual
discrimination.
Cataleptic Potential of Compounds in C57BL/6 Mice
An important aspect for new generations of APDs is
determining whether they possess motor side effects. In the
horizontal bar test mice were evaluated before (baseline) and
60 min after treatment. Catalepsy at baseline was similar
across all groups (range 0.0–1.0 s). Compared with vehicle,
haloperidol produced significant catalepsy at 1 and 10 mg/kg
(P-valueso0.001), which were not significantly different
Figure 3 The three JJ compounds and lorcaserin improved novel object recognition memory (NORM) in NR1-knockdown (NR1-KD) mice; however, JJ-3-
45 was unable to restore reversal discrimination performance in MK-801-treated C57BL/6J mice. (a and b) Responses at training and at testing 24 h later in
NORM with wild-type (WT) and NR1-KD mice. (a) The investigations were conducted with WT mice using different doses of JJ-3-45, JJ-3-42, JJ-5-34, and
lorcaserin. (b) The same experiments were run with NR1-KD mice. A repeated-measures analysis of variance (RMANOVA) for JJ-3-45 within-subjects effect
of time (F(1,46)= 59.964, Po0.001), time by genotype (F(1,46)= 8.521, P= 0.005), time by treatment (F(2,46)= 3.110, P= 0.054), and time by genotype by
treatment (F(2,46)= 13.318, Po0.001) interactions; between-subjects effects of genotype (F(1,46)= 12.403, Po0.001), genotype by treatment interaction (F
(2,46)= 12.136, Po0.001). The RMANOVA for JJ-3-42 within-subjects time effect (F(1,60)= 73.254, Po0.001), time by genotype (F(1,60)= 32.444,
Po0.001) and time by genotype by treatment (F(3,60)= 9.676, Po0.001) interactions; between-subjects genotype effect (F(1,60)= 19.730, Po0.001),
genotype by treatment interaction (F(3,60)= 7.672, Po0.001). A RMANOVA for JJ-5-34 within-subjects effects of time (F(1,48)= 40.152, Po0.001), time by
genotype (F(1,48)= 6.975, P= 0.011), time by treatment (F(2,48)= 4.892, P= 0.012), and time by genotype by treatment (F(2,48)= 8.493, Po0.001)
interactions; between-subjects effects of genotype (F(1,48)= 7.745, P= 0.008), genotype by treatment interaction (F(2,48)= 8.455, P= 0.001). The
RMANOVA for lorcaserin within-subjects main effects for time (F(1,26)= 59.239, Po0.001), time by genotype (F(1,46)= 16.858, Po0.001) and time by
genotype by treatment (F(2,46)= 15.199, Po0.001) interactions; between-subject tests for the genotype (F(1,46)= 20.639, Po0.001), genotype by
treatment interaction (F(2,46)= 20.269, Po0.001). (c–f) Visual discrimination performance and reversal in C57BL/6J mice treated with vehicle, MK-801, or
MK-801 plus JJ-3-45. (c) Baseline performance on the visual discrimination is presented as the numbers of correct responses, numbers of errors, and percent
correct responses for groups given vehicle, MK-801, or JJ-3–45 plus MK-801. (d) Number of correct responses during the last two days of visual discrimination
followed by reversal testing. A RMANOVA for the numbers of correct trials: within-subject effect of session (F(15,270)= 50.264, Po0.001), session by
treatment interaction (F(30,270)= 4.828, Po0.001); between subject effect of treatment (F(2,18)= 16.831, Po0.001). (e) Number of errors over the same
course of testing. A RMANOVA for the number of errors: within-subjects effects for session (F(15,270)= 60.559, Po0.001), session by treatment interaction
(F(30,270)= 2.664, Po0.001); between-subjects effect of treatment (F(2,18)= 35.288, Po0.001). (f) Percent correct responses over the same course of
testing. A RMANOVA for the percent of correct responses: within-subjects effects of session (F(15,270)= 59.741, Po0.001), session by treatment interaction
(F(30,270)= 5.251, Po0.001); between-subjects effect of treatment (F(2,18)= 17.346, Po0.001). N= 8–10 mice per drug or compound per dose in NORM
and N= 5–10 mice per treatment in the reversal visual discrimination test; *Po0.05, compared with the vehicle group or the vehicle within genotype;
#Po0.05, compared with the WT vehicle control.
Table 3 Duration of Contacts in the Novel Object Recognition Memory Test in WT and NR1-KD Mice
Veh JJ-3-45 JJ-3-42 JJ-5-34 Lorcaserin
mg/kg 0 1 5 1 5 10 1 5 0.5 1
Traininga
WT 65.9± 17.0 57.8± 11.0 38.8± 7.8 48.0± 6.2 34.5± 5.8 34.8± 5.8 44.6± 5.2 44.4± 8.4 46.1± 5.5 42.4± 2.0
KD 84.3 ± 15.0 109.7± 18.0 93.0± 13.7 91.9± 18.0 91.8± 16.0 70.4± 11.0 119.9 ± 18.0 87.6± 14.0 74.0± 9.0 79.5± 12.0
Testb
WT 59.5± 4.3 65.9± 13.0 42.4± 8.3 39.1± 8.1 19.4± 4.5 29.8± 5.9 43.9± 6.8 49.6± 20.5 72.9± 11.0 31.9± 5.0
KD 78.5 ± 17.0 107.2± 11.1 76.4± 11.0 79.8± 4.0 70.7± 10.0 42.9± 5.7 122.8 ± 13.0 84.1± 17.0 54.7± 8.0 77.1± 11.0
Abbreviations: NR1-KD, NR1-knockdown; RMANOVA, repeated-measures analysis of variance; Veh, vehicle; WT, wild type.
aResults are presented as means ± SEM; N= 8–10 mice per drug or compound per dose.
bRMANOVA: within-subjects effects of time (F(1,146)= 4.527, P= 0.035) and time by genotype interaction (F(1,146)= 4.055, P= 0.046); between-subjects effects of
genotype (F(1,146)= 66.186, Po0.001) and treatment (F(9,146)= 2.648, P= 0.007); there was a trend for the genotype by treatment interaction (F(9,146)+1.785,
P= 0.076) to be significant.
from each other (Figure 4). Additionally, responses to 1 and
10 mg/kg haloperidol were significantly higher than those to
lower doses of haloperidol and all other compounds
(P-valueso0.001). Thus, the novel 5-HT2C compounds and
lorcaserin do not produce catalepsy at doses that elicit it with
haloperidol.
Effects of JJ-3-42 and Lorcaserin on In Vivo Brain
Neurotransmitter Release
5-HT2C receptors are G-protein-coupled receptors expressed
on GABAergic, glutamatergic, and dopaminergic neurons
(Bubar et al, 2011; McCorvy and Roth, 2015; Nocjar et al,
2015). These receptors are present in cortical areas,
hippocampus, ventral midbrain, striatum, NAc, hypothala-
mus, and amygdala (Jensen et al, 2010). Microdialysis studies
were conducted to determine whether a 5-HT2C agonist or
lorcaserin could influence neurotransmitter efflux in mouse
infralimbic cortex or striatum. In infralimbic cortex, 10 mg/
kg JJ-3-42 significantly reduced DA (P= 0.040), 5-HT
(P= 0.014), DOPAC (P= 0.003), and HVA (P= 0.006),
whereas 1 mg/kg lorcaserin decreased DA (P= 0.021) and
HVA (P= 0.050) compared with vehicle (Figure 5a). In the
striatum, only JJ-3-42 significantly decreased DA efflux
(P= 0.021) (Figure 5b). All other neurotransmitter levels
were not significantly different among treatments.
Responses to JJ-3-42 and lorcaserin on cortical and striatal
DA efflux over time are displayed in Figures 5c and d,
respectively. In these brain regions, no significant pre-
treatment effects were observed at baseline (−90, − 60, − 30,
and 0 min). At 90 min postinjection, infralimbic cortex
extracellular DA levels were decreased with lorcaserin
(P= 0.029) and they were even more suppressed with JJ-3-
42 relative to the vehicle control (P= 0.004) (Figure 5c). DA
levels were still depressed at 120 min with JJ-3-42
(P-valueso0.031), whereas levels recovered to those of the
vehicle with lorcaserin. In contrast, striatal DA levels were
reduced at 60, 90, and 150 min postinjection with JJ-3-42
(P-valueso0.029), but not with lorcaserin (Figure 5d).
Collectively, JJ-3-42 exerts more marked effects than
lorcaserin on DA efflux in infralimbic cortex and only
JJ-3-42 reduced DA in the striatum.
DISCUSSION
New medications to treat positive, negative, and cognitive
symptoms of SZ that have superior efficacy and fewer side
effects than typical and atypical APDs are crucial to achieve
better outcomes in various psychotic disorders. In this
regard, compounds that can modulate DA release such as
5-HT2C-selective agonists (Cheng et al, 2015, 2016) show some
promise. In the present study, we provide behavioral profiles of
three novel selective 5-HT2C agonists in models of SZ-like
behaviors and have analyzed one of the compounds
and lorcaserin on neurotransmitter efflux. It should be empha-
sized that our results are relevant to SZ because clinical
trials were completed in 2014 for a 5-HT2C-selective drug
(https://clinicaltrials.gov/ct2/show/results/NCT00563706?sect=
X543016#limit).
JJ-3-42 and JJ-3-45 are structurally unique compounds that
show good potency and excellent selectivity for the 5-HT2C
receptor (Cheng et al, 2015, 2016). Both compounds are 5-
HT2C agonists (EC50s of 4.2 and 3.4 nM for JJ-3-42 and JJ-3-
45, respectively), with ~ 100-fold selectivity against 5-HT2A
as partial agonists (Emax= 56 and 76% for JJ-3-42 and JJ-3-
45, respectively). Most importantly, these compounds show
no significant activation of 5-HT2B receptors at concentra-
tions up to 10 μM, whereas lorcaserin is a full agonist with
moderate potency in our assay (EC50= 478 nM, Emax= 92%).
JJ-5-34 is comprised of a benzofuran scaffold and it activates
the 5-HT2C receptor with an EC50 of 23 nM (Emax= 102%). It
is a very weak 5-HT2B agonist (EC50= 433 nM, Emax= 19%),
with no activation of 5-HT2A receptors up to 10 μM (results
to be published). Besides their excellent pharmacological
profiles, in CD-1 mice all three compounds have excellent
brain penetration properties, with brain/plasma concentra-
tion ratios 45 at all time-points tested (data not shown).
These high brain concentrations indicate that the JJ
compounds may be actively transported into the brain,
which is ideal for CNS-targeted therapeutics. Despite their
excellent profile, the compounds may have some activities
that were not assayed. Regardless, all three JJ compounds
represent excellent pharmacological tools for exploring the
therapeutic effects of 5-HT2C-selective agonists in SZ models
and they represent potential 5-HT2C receptor drug candi-
dates for further development.
Acute AMPH-induced hyperactivity is used as an animal
model for acute psychosis as AMPH administration to SZ
patients exacerbates the florid symptomatology (Angrist
et al, 1980). All three JJ compounds dose-dependently
reduced AMPH-stimulated hyperlocomotion. With the
exception of 30 mg/kg JJ-3-45, these effects did not affect
baseline activity. JJ-3-42 and JJ-5-34 depressed AMPH-
induced hyperactivity to levels that were statistically indis-
tinguishable from vehicle controls. JJ-3-45 was not as
efficacious since activity with 20 mg/kg was still significantly
higher than vehicle, whereas 30 mg/kg significantly de-
pressed baseline locomotion. By comparison, lorcaserin
had a stimulatory effect on baseline activity at the lowest
dose and the reduction in AMPH-induced hyperlocomotion
was not dose-dependent—suggesting a complex mechanism
of action (see Devroye et al, 2015).
Atypical APDs exert their actions through antagonism of
D2, inverse agonism at 5-HT2A, and various actions at 5-H1A,
5-HT6, and 5-HT7 receptors—depending on the drug
Figure 4 The three JJ compounds and lorcaserin have low cataleptic
potential in C57BL/6J mice compared with haloperidol in the horizontal bar
test. Dose responses with haloperidol, JJ-3-45, JJ-3-42, JJ-5-34, and lorcaserin
for catalepsy. An analysis of variance (ANOVA) between-subjects effects of
treatment (F(20,175)= 18.511, Po0.001). N= 8–12 mice per compound
or drug dose; *Po0.05, compared with the vehicle control; ‡Po0.05, 1 or
10 mg/kg haloperidol compared with all other doses and compounds.
administered (Meltzer and Huang, 2008). Typical APDs act
primarily through D2 receptor blockade. The novel JJ
compounds do not block DA receptors (Cheng et al, 2016).
However, they reduce DA receptor stimulation by decreasing
DA release and by acting on 5-HT2C receptors on
GABAergic neurons in the substantia nigra and VTA
(Gobert et al, 2000). This latter mode of action may underlie
the lack of significant cataleptic potential of JJ compounds.
Although lorcaserin produced catalepsy over baseline; this
response was not significantly higher compared with that to
vehicle. With regard to JJ compounds, it should be
emphasized that at 20 mg/kg, each compound significantly
antagonized open-field AMPH-stimulated hyperactivity
while producing no catalepsy in the horizontal bar test. By
comparison, typical APDs with relatively selective D2
antagonism as well as atypical APDs produce similar
reductions in AMPH-induced hyperlocomotion at doses that
yield significant depressions in baseline activity or produce
catalepsy (Schaefer and Michael, 1984).
PPI is disrupted in acute psychosis (Meincke et al, 2004)
and it is perturbed in rodents by direct and indirect DA
agonists (Geyer and Moghaddam, 2002). Both typical and
atypical APDs reverse these effects. JJ-3-42 and JJ-5-34 at 1 to
4 mg/kg normalized AMPH-disrupted PPI to the vehicle
control; JJ-3-45 and lorcaserin at 0.5 mg/kg were more
efficacious. These doses were much lower than those needed
Figure 5 JJ-3-42 and lorcaserin decrease dopamine efflux in infralimbic cortex, whereas only the JJ compound reduced it in the striatum of C57BL/6J mice.
Baseline values were collected and then mice were injected (time 0) with vehicle, 10 mg/kg JJ-3-42, or 1 mg/kg lorcaserin and samples were collected over
180 min. Absolute baseline levels can be found in Supplementary Table S1. (a) Extracellular neurotransmitter and metabolite levels in the infralimbic cortex
expressed as area under the curve (AUC) representing the mean values from 0 to 180 min. In infralimbic cortex, the following neurotransmitter efflux levels
were significant by Kruskal–Wallis H tests: dopamine (DA) (P= 0.035), serotonin (5-HT) (P= 0.009), 3,4-dihydroxyphenylacetic acid (DOPAC) (P= 0.002),
and homovanillic acid (HVA) (P= 0.016). (b) Efflux of neurotransmitter and metabolites in the striatum displayed as area under the curve (AUC). The Kruskal–
Wallis H test discerned a significant effect for DA (P= 0.042) and a trend for HVA (P= 0.075). (c) Extracellular DA levels in the infralimbic cortex at baseline
(−90, − 60, − 30, and 0 min) and subsequently (30, 60, 90, 120, 150, and 180 min) postinjection to the vehicle, JJ-3-42, and lorcaserin. A repeated-measures
analysis of variance (RMANOVA) for responses at baseline (−90 to 0 min) to 180 min: within-subjects effects of time (F(6,114)= 3.927, Po0.001), time by
treatment interaction (F(12.114)= 1.943, P= 0.036); between-subjects effects of treatment (F(2,19)= 5.458, P= 0.013). (d) Extracellular DA levels in the
striatum during baseline and following exposure to the vehicle, JJ-3-42, and lorcaserin. Kruskal–Wallis H tests for DA at 60, 90, and 150 min (P-valueso0.054).
N= 7–9 mice per treatment; *Po0.05, compared with the vehicle group; xPo0.05, lorcaserin vs JJ-3-42.
to affect baseline open field locomotion or antagonize the
AMPH-induced hyperactivity. By comparison, the doses of
conventional APDs used to normalize AMPH-disrupted PPI
(Brody et al, 2004; Feifel et al, 1999; Swerdlow et al, 2005) are
in the range of doses that can affect baseline locomotion or
block AMPH-induced hyperlocomotion, while the atypical
APD clozapine restores PPI at 20 mg/kg, it does not
normalize locomotion in rats (Cáceda et al, 2005). Thus, JJ
compounds display superior efficacy in normalizing PPI in
the AMPH model and they may possess a broader
therapeutic index than typical APDs for treating acute
psychosis.
Some negative symptoms of SZ amenable to modeling in
animals are motivational impairment and diminished social
drive (Kirkpatrick et al, 2000). Second-generation APDs
partially ameliorate negative symptoms (Leucht et al, 1999)
and D2/D3 antagonists may cause secondary negative
symptoms (Heinz et al, 1998). To assess motivation, we
used a progressive ratio schedule of food reinforcement.
Breakpoint in rodents is correlated with the magnitude of
sucrose reward (Young and Markou, 2015) and with exertion
of effort (Salamone and Correa, 2012). Effort-based tasks
have been proposed for modeling motivational abnormalities
in SZ based on preserved hedonic responses to primary
rewards (Young and Markou, 2015). We found all three JJ
compounds and lorcaserin reduced breakpoints in the same
dose ranges that were effective in antagonizing AMPH-
disrupted PPI. In this respect, the selective 5-HT2C ligands
behaved similar to typical APDs (Salamone et al, 1991).
Hence, these compounds may not have the potential to
reverse motivation-related deficits in SZ, which continue to
be a challenging area in the management of SZ.
Currently, the nature of impaired social interactions in SZ
is obscure where they may have complex relationships with
positive and negative symptoms, reflect social anxiety
(Millan and Bales, 2013), or perturbed executive function
(Meltzer et al, 1996). Hence, social behavior in animal
models of SZ should be interpreted with caution. Never-
theless, a commonly used procedure with rodents is the
sociability test (Moy et al, 2004). This test examines social
affiliation, which may represent motivation to spend time
with a conspecific vs an inanimate object and social
preference, which denotes an ability to differentiate between
familiar and novel social stimuli. We applied this test to
NR1-KD mice, which are considered to mimic the hypothe-
sized NMDAR hypofunction in SZ and are hyperactive in the
open field, impaired in PPI, and deficient in sociability
(Mohn et al, 1999; Park et al, 2016).
All three selective 5-HT2C agonists and lorcaserin sig-
nificantly improved social affiliation in NR1-KD mice in a
dose range similar to clozapine. Although clozapine in-
creased social affiliation in mutants to that of WT vehicle
controls, their overall levels of social behavior were lower.
The results in NR1-KD mice appear more marked than in SZ
patients where clozapine exerts only modest effects on
psychosocial functioning as measured with the Quality of
Life Scale and other questionnaires that assess social
functioning and activities of daily living (Swartz et al, 2007;
Guo et al, 2012). In a previous study, diazepam improved the
abilities of NR1-KD mice to prefer social over non-social
stimuli (Milenkovic et al, 2014). It remains to be seen
whether the selective 5-HT2C agonists possess anxiolytic
properties like diazepam. In this respect, an HTR2c
polymorphism has been associated with enhanced accumbal
DA release during pain stress (Mickey et al, 2012). Hence, by
acting on the mesolimbic DA system, selective 5-HT2C
agonists may possess anxiolytic actions and ameliorate stress
responses.
The NR1-KD mice were impaired also in social preference.
Since there was a 1–2 min delay between the social affiliation
and social preference tests, this deficit is unlikely to represent
impaired memory function. Clozapine failed to improve
social preference in NR1-KD subjects; however, other doses
may be more effective. By comparison, lower doses of JJ-3-45
and JJ-3-42 and higher doses of JJ-5-34 and lorcaserin
improved social preference in these mutants. While the
underlying mechanism requires additional investigation, one
process relevant to SZ symptomatology may be deficient
encoding of information. For instance, a discrimination of
social novelty requires selective attention and this can be
disrupted by acute or neonatal phencyclidine treatment that
is sensitive to clozapine (Terranova et al, 2005). While
attention has not been assessed in NR1-KD mice, blockade of
NMDARs in frontal cortex reduces accuracy in the 5-choice
serial reaction-time task in rodents due to ‘distractability’
(Carli and Invernizzi, 2014). Thus, it is possible that 5-HT2C
agonists may affect selective attention independent of
memory processes in NR1-KD mice.
In addition to various psychosocial symptoms, non-verbal
memory deficits in SZ are well documented, especially for
incidental visual memory (Seidman et al, 2003). A deficit in a
subtype of long-term memory termed episodic memory is
considered a core deficit in SZ (Clare et al, 1993) and the
NORM task requires intact visual memory for a previously
encountered item (see Ennaceur and Delacour, 1988). JJ-3-
45, JJ-5-34, and lorcaserin reversed the NR1-KD impairment
in NORM at 1 mg/kg. Parenthetically, this same dose
restored social affiliation in these mutants. By comparison,
JJ-3-42 normalized NORM in NR1-KD mice at 5 mg/kg.
Higher doses of all compounds were not efficacious—
suggesting an optimum for stimulation of 5-HT2C receptors
in this task.
Another cognitive symptom of SZ pertains to an inability
to suppress a previous response when it becomes irrelevant
and this deficiency has been attributed to reduced sensitivity
to negative feedback (Leeson et al, 2009). This condition,
perseveration, can be modeled by reversing the contingencies
of a simple visual discrimination (Bussey et al, 2012). With
this paradigm, we examined effects of chronically adminis-
tering JJ-3-45 to mice given the NMDAR antagonist MK-801,
as another model for cognitive impairment in SZ (van der
Meulen et al, 2003). We empirically selected a dose of
MK-801 that did not perturb visual discrimination perfor-
mance but significantly retarded both the learning of a new
contingency and the extinction of the prepotent response to
the irrelevant stimulus. Here, mice treated with MK-801
made more errors after stimulus reversal and only by the end
of 14 days of testing did they approach the accuracy of
vehicle controls. Reversal learning depends upon the 5-HT
system and Alsiö et al (2015) found that systemic 5-HT2C
antagonism alleviated early (ie, occurring before achieving
50% correct responses) perseverative errors. Our results with
the agonist JJ-3-45 agree with this finding where this
compound potentiated the effects of MK-801-induced
perseveration as demonstrated by a higher proportion of
errors from the beginning of reversal through the final
sessions, compared with MK-801 treatment alone. Thus,
selective 5-HT2C agonists may have the potential to
exacerbate this executive-function deficit in SZ.
5-HT2C receptors are expressed on GABAergic, glutama-
tergic, and dopaminergic neurons (Bubar et al, 2011;
McCorvy and Roth, 2015; Nocjar et al, 2015). 5-HT2C
agonists (eg, WAY 163909, CP-809101, and vabicaserin)
have been proposed to offer potential antipsychotic efficacy
without possessing the traditional side-effects associated with
current APDs (Dunlop et al, 2006; Marquis et al, 2007;
Siuciak et al, 2007; Aloyo et al, 2009; Jensen et al, 2010;
Rosenzweig-Lipson et al, 2012; Liu et al, 2014; Cheng et al,
2015). These agonists can reduce basal firing rates and
bursting activity of DA neurons and exert an excitatory effect
on many GABAergic neurons in the VTA (Invernizzi et al,
2007; Di Giovanni et al, 2000), suggesting a possible
mechanism of action for these agonists. In a microdialysis
study with rats, 5-HT2C agonists (ie, WAY 163909, Ro-61-
0175, and MK 212) decreased DA in the medial prefrontal
cortex and NAc, while increasing ACh efflux in the
prefrontal cortex and hippocampus (Millan et al, 1998;
Nair and Gudelsky, 2004; Marquis et al, 2007). We found
that 10 mg/kg JJ-3-42 and 1mg/kg lorcaserin reduced
infralimbic DA efflux, while only JJ-3-42 successfully
decreased it in striatum—suggesting that their mechanisms
of actions may be different. Since the DA hypothesis of SZ
postulates that extracellular DA levels are low in cortex and
high in striatum (see Weinstein et al, 2016), it is possible that
5-HT2c agonists may exacerbate some symptoms of SZ by
further reducing cortical DA. Nevertheless, these findings
support the hypothesis that 5-HT2C receptors in the NAc and
VTA negatively regulate DA efflux from dopaminergic
neurons (O’Neil, 2010). Our findings suggest that JJ-3-42
may stimulate 5-HT2C receptors in the NAc or VTA, and
thereby inhibit dopaminergic neurons that project to the
frontal cortex and striatum, respectively. Other APD-like
mechanisms of 5-HT2C agonists may include modification of
signaling pathways and trafficking, as well as RNA-editing
changes that have been associated with SZ (Rosenzweig-
Lipson et al, 2012).
SZ is a complex neuropsychiatric disorder and responses
to APDs are heterogeneous. Despite multiple actions at D2
and other receptors, most APDs are efficacious in treating
positive symptoms but are less robust for treating negative
and cognitive symptoms (Leucht et al, 2009; Miyamoto et al,
2012). In the present studies, we demonstrate that the
5-HT2C agonists—JJ-3-45, JJ-3-42, and JJ-5-34—are mostly
efficacious in ameliorating a broad range of SZ-like
behaviors in mice. Importantly, these compounds show
efficacy in mice with persistent NMDAR hypofunctioning
and in the hyperdopaminergic AMPH model of SZ. While
we do not know whether 5-HT2C agonists will be efficacious
in treating patients, the ability of these ligands to modulate
dopaminergic activities in the frontal cortex and striatum
may provide a unique opportunity to develop drugs with
fewer side effects, greater therapeutic selectivity, and
enhanced efficacy for treating SZ and related disorders than
current APDs.
FUNDING AND DISCLOSURE
The authors declare no conflict of interest.
ACKNOWLEDGMENTS
We thank Shaina Gong, Vineet Nadkarni, Paul Skiba,
Christopher Means, Liza Stephanz, Theodore Rhodes, and
Aran Marati for assisting with some of the behavioral testing
and Jiechun Zhou for genotyping and maintaining the mice.
Some of the behavioral experiments were conducted with
equipment and software purchased with a North Carolina
Biotechnology Center grant. We also received the NR1 mice
from Dr Amy J Ramsey (University of Toronto, Toronto,
ON, Canada) and they were further backcrossed for more
than 10 generations to C57BL/6 and 129X1/Sv mice as
separate lines. We have no competing interests in relation to
the work described herein. Dr Roth has received compensa-
tion as Deputy Editor of the Journal of Clinical Investigation
and as consultant over the past 12 months from Pfizer
Pharmaceuticals. Dr Roth has received research support
from Merck Pharmaceuticals and Asubio Pharmaceuticals
over the past 12 months. Dr Wetsel has received research
support over the past 12 months from Rugen Holdings
(Cayman) Limited. Dr Meltzer has received funding from
Sumitomo Dainippon, Sunovion, Janssen Pharmaceuticals,
Auspex, Lundbeck, and the Weisman Family Foundation.
Drs Meltzer, Roth, Kozikowski, and Wetsel receive NIH
funding. We are indebted to the NIMH (Grant No.
R01MH99993) for financial support for this work. Some
work in this manuscript from Drs Roth and Wetsel was
supported by U19MH082441.
REFERENCES
Abdallah L, Bonasera SJ, Hopf FW, O'Dell L, Giorgetti M,
Jongsma M et al (2009). Impact of serotonin 2C receptor null
mutation on physiology and behavior associated with nigros-
triatal dopamine pathway function. J Neurosci 29: 8156–8165.
Alex KD, Yavanian GJ, McFarlane HG, Pluto CP, Pehek EA (2005).
Modulation of dopamine release by striatal 5-HT2C receptors.
Synapse 55: 242–251.
Aloyo VJ, Berg KA, Spampinato U, Clarke WP, Harvey JA (2009).
Current status of inverse agonism at serotonin 2A (5-HT2A) and
5-HT2C receptors. Pharmacol Ther 121: 160–173.
Alsiö J, Nilsson SR, Gastambide F, Wang RA, Dam SA, Mar AC
et al (2015). The role of 5-HT2C receptors in touchscreen visual
reversal learning in the rat: a cross-site study. Psychopharmacol-
ogy (Berl) 232: 4017–4031.
Angrist B, Rotrosen J, Gershon S (1980). Differential effects of
amphetamine and neuroleptics on negative vs. positive symptoms
in schizophrenia. Psychopharmacology (Berl) 72: 17–19.
Arciniegas DB, Topkoff JL, Held K, Frey L (2001). Psychosis
due to neurologic conditions. Curr Treat Options Neurol 3:
347–366.
Brody SA, Conquet F, Geyer MA (2004). Effect of antipsychotic
treatment on the prepulse inhibition deficit of mGluR5 knockout
mice. Psychopharmacology 172:187–195.
Bubar MJ, Stutz SJ, Cunningham KA (2011). 5-HT2C receptors
localize to dopamine and GABA neurons in the rat mesoaccum-
bens pathway. PLoS One 6: e20508.
Bussey TJ, Holmes A, Lyon L, Mar AC, McAllister KA,
Nithianantharajah J et al (2012). New translational assays for
preclinical modelling of cognition in schizophrenia: the
touchscreen testing method for mice and rats. Neuropharmacol-
ogy 62: 1191–1203.
Cáceda R, Kinkead N, Owens MJ, Nemeroff CB (2005). Virally
mediated increased neurotensin 1 receptor in the nucleus
accumbens decreases behavioral effects of mesolimbic system
activation. J Neurosci 25: 11748–11756.
Carli M, Invernizzi RW (2014). Serotoninergic and dopaminergic
modulation of cortico-striatal circuit in executive and attention
deficits induced by NMDA receptor hypofunction in the 5-choice
serial reaction time task. Front Neural Circuits 8: 58.
Cheng J, Giguère PM, Onajole OK, Lv W, Gaisin A, Gunosewoyo H
et al (2015). Optimization of 2-phenylcyclopropylmethylamines
as selective serotonin 2C receptor agonists and their evaluation as
potential antipsychotic agents. J Med Chem 58: 1992–2002.
Cheng J, Giguère PM, Schmerberg CM, Pogorelov VM, Rodriguiz RM,
Huang XP et al (2016). Further advances in optimizing
(2-phenylcyclopropyl)methylamines as novel serotonin 2C agonists:
effects on hyperlocomotion, prepulse inhibition, and cognition
models. J Med Chem 59: 578–591.
Clare L, McKenna PJ, Mortimer AM, Baddeley AD (1993). Memory
in schizophrenia: What is impaired and what is preserved?
Neuropsychologia 31: 1225–1241.
Conn PJ, Sanders-Bush E, Hoffman BJ, Hartig PR (1986). A unique
serotonin receptor in choroid plexus is linked to phosphatidyli-
nositol turnover. Proc Natl Acad Sci USA 83: 4086–4088.
Désaméricq G, Schurhoff F, Meary A, Szöke A, Macquin-Mavier I,
Bachoud-Lévi AC et al (2014). Long-term neurocognitive effects
of antipsychotics in schizophrenia: a network meta-analysis. Eur J
Clin Pharmacol 70: 127–134.
Devroye C, Cathala A, Maitre M, Piazza PV, Abrous DN,
Revest JM et al (2015). Serotonin 2C receptor stimulation inhibits
cocaine-induced Fos expression and DARPP-32 phosphorylation
in the rat striatum independently of dopamine outflow.
Neuropharmacology 89: 375–381.
Di Giovanni G, Di Matteo V, Di Mascio M, Esposito E (2000).
Preferential modulation of mesolimbic vs. nigrostriatal dopami-
nergic function by serotonin2C/2B receptor agonists: a combined
in vivo electrophysiological and microdialysis study. Synapse 35:
53–61.
Dunlop J, Marquis KL, Lim HK, Leung L, Kao J, Cheesman C et al
(2006). Pharmacological profile of the 5-HT2C receptor agonist
WAY-163909; therapeutic potential in multiple indications. CNS
Drug Rev 12: 167–177.
Eberle-Wang K, Mikeladze Z, Uryu K, Chesselet MF (1997). Pattern
of expression of the serotonin2C receptor messenger RNA in the
basal ganglia of adult rats. J Comp Neurol 384: 233–247.
Ennaceur A, Delacour J (1988). A new one-trial test for
neurobiological studies of memory in rats. 1: Behavioral data.
Behav Brain Res 31: 47–59.
Feifel D, Reza T, Robeck S (1999). Antipsychotic potential of CCK-
based treatments: an assessment using the prepulse inhibition
model of psychosis. Neuropsychopharmacology 20:141–149.
Geyer MA, Moghaddam B (2002). Animal models relevant to
schizophrenia disorders. In: David KL, Charney D, Coyle JT,
Nemeroff C (eds). Neuropsychopharmacology: The Fifth Genera-
tion of Progress. Lippincott Williams & Wilkins: Philadelphia, PA.
pp 689–701.
Gobert A, Rivet JM, Lejeune F, Newman-Tancredi A, Adhumeau-
Auclair A, Nicolas JP et al (2000). Serotonin2C receptors tonically
suppress the activity of mesocortical dopaminergic and adrener-
gic, but not serotonergic pathways: a combined dialysis and
electrophysiological analysis in the rat. Synapse 36: 205–221.
Grottick AJ, Fletcher PJ, Higgins GA (2000). Studies to investigate
the role of 5-HT2C receptors on cocaine- and food-maintained
behavior. J Pharmacol Exp Ther 295: 1183–1191.
Guo X, Zhang Z, Zhai J, Fang M, Hu M, Wu R et al Early-stage
Schizophrenia Outcome Study Investigators (2012). Effects of
antipsychotic medications on quality of life and psychosocial
functioning in patients with early-stage schizophrenia:
1-year follow-up naturalistic study. Compr Psychiatry 53:
1006–1012.
Heinz A, Knable MB, Coppola R, Gorey JG, Jones DW, Lee KS et al
(1998). Psychomotor slowing, negative symptoms and dopamine
receptor availability—an IBZM SPECT study in neuroleptic-
treated and drug-free schizophrenic patients. Schizophr Res 31:
19–26.
Invernizzi RW, Pierucci M, Calcagno E, Di Giovanni G, Di Matteo V,
Benigno A et al (2007). Selective activation of 5-HT2C recep-
tors stimulates GABA-ergic function in the rat substantia nigra
pars reticulata: a combined in vivo electrophysiological and
neurochemical study. Neuroscience 144: 1523–1535.
Jensen NH, Cremers TI, Sotty F (2010). Therapeutic potential of
5-HT2C receptor ligands. Scientific World J 10: 1870–1885.
Kegeles LS, Abi-Dargham A, Frankle WG, Gil R, Cooper TB,
Slifstein M et al (2010). Increased synaptic dopamine function in
associative regions of the striatum in schizophrenia. Arch Gen
Psychiatry 67: 231–239.
Kirkpatrick B, Kopelowicz A, Buchanan RW, Carpenter WT Jr
(2000). Assessing the efficacy of treatments for the deficit
syndrome of schizophrenia. Neuropsychopharmacology 22:
303–310.
Krystal JH, D'Souza DC, Petrakis IL, Belger A, Berman RM,
Charney DS et al (1999). NMDA agonists and antagonists as
probes of glutamatergic dysfunction and pharmacotherapies in
neuropsychiatric disorders. Harv Rev Psychiatry 7: 125–143.
Landqvist-Waldö M, Gustafson L, Passant U, Englund E (2015).
Psychotic symptoms in frontotemporal dementia: a diagnostic
dilemma? Int Psychogeriatr 27: 531–539.
Leeson VC, Robbins TW, Matheson E, Hutton SB, Ron MA,
Barnes TR et al (2009). Discrimination learning, reversal, and set-
shifting in first-episode schizophrenia: stability over six years and
specific associations with medication type and disorganization
syndrome. Biol Psychiatry 66: 586–593.
Leucht S, Pitschel-Walz G, Abraham D, Kissling W (1999). Efficacy
and extrapyramidal side-effects of the new antipsychotics
olanzapine, quetiapine, risperidone, and sertindole compared to
conventional antipsychotics and placebo. A meta-analysis of
randomized controlled trials. Schizophr Res 35: 51–68.
Leucht S, Arbter D, Engel RR, Kissling W, Davis JM (2009).
How effective are second-generation antipsychotic drugs? A
meta-analysis of placebo-controlled trials. Mol Psychiatry 14:
429–447.
Liu J, Ogden A, Comery TA, Spiros A, Roberts P, Geerts H (2014).
Prediction of efficacy of vabicaserin, a 5-HT2C agonist, for the
treatment of schizophrenia using a quantitative systems
pharmacology model. CPT Pharmacometrics Syst Pharmacol 3:
e111.
López-Gil X, Artigas F, Adell A (2010). Unravelling monoamine
receptors involved in the action of typical and atypical
antipsychotics on glutamatergic and serotonergic transmission
in prefrontal cortex. Curr Pharm Des 16: 502–515.
Marquis KL, Sabb AL, Logue SF, Brennan JA, Piesla MJ, Comery TA
et al (2007). WAY-163909[(7bR,10aR)-1,2,3,4,8,9,10,10a-octa-
hydro-7bH-cyclopenta-[b][1,4]diazepino [6,7,1hi]indole]: a novel
5-hydroxytryptamine 2C receptor-selective agonist with pre-
clinical antipsychotic-like activity. J Pharmacol Exp Ther 320:
486–496.
McCorvy JD, Roth BL (2015). Structure and function of serotonin
G-protein coupled receptors. Pharmacol Ther 150: 129–142.
Meincke U, Mörth D, Voss T, Thelen B, Geyer MA, Gouzoulis-
Mayfrank E (2004). Prepulse inhibition of the acoustically evoked
startle reflex in patients with an acute schizophrenic psychosis—a
longitudinal study. Eur Arch Psychiatry Clin Neurosci 254:
415–421.
Meltzer HY (2015). Pharmacotherapy of cognition in schizophre-
nia. Curr Opin Behav Sci 4: 115–121.
Meltzer HY, Matsubara S, Lee JC (1989). Classification of typical
and atypical antipsychotic drugs on the basis of dopamine D-1,
D-2, and serotonin2 pKi values. J Pharmacol Exp Ther 251:
238–246.
Meltzer HY, Thompson PA, Lee MA, Ranjan R (1996). Neurop-
sychologic deficits in schizophrenia: relation to social function
and effect of antipsychotic drug treatment. Neuropsychopharma-
cology 14(Suppl): 27S–33S.
Meltzer HY, Huang M (2008). In vivo actions of atypical
antipsychotic drug on serotonergic and dopaminergic systems.
Prog Brain Res 172: 177–197.
Mickey BJ, Sanford BJ, Love TM, Shen PH, Hodgkinson CA,
Stohler CS et al (2012). Striatal dopamine release and genetic
variation of the serotonin 2C receptor in humans. J Neurosci 32:
9344–9350.
Milenkovic M, Mielnik CA, Ramsey AJ (2014). NMDA receptor-
deficient mice display sexual dimorphism in the onset and severity
of behavioural abnormalities. Genes Brain Behav 13: 850–862.
Millan MJ, Dekeyne A, Gobert A (1998). Serotonin (5-HT)2C
receptors tonically inhibit dopamine (DA) and noradrenaline
(NA), but not 5-HT, release in the frontal cortex in vivo.
Neuropharmacology 37: 953–955.
Millan MJ, Bales KL (2013). Towards improved animal models for
evaluating social cognition and its disruption in schizophrenia:
the CNTRICS initiative. Neurosci Biobehav Rev 37: 2166–2180.
Miyamoto S, Duncan GE, Marx CE, Lieberman JA (2005).
Treatments for schizophrenia: a critical review of pharmacology
and mechanisms of action of antipsychotic drugs. Mol Psychiatry
10: 79–104.
Miyamoto S, Miyake N, Jarskog LF, Fleischhacker WW, Lieberman JA
(2012). Pharmacological treatment of schizophrenia: a critical
review of the pharmacology and clinical effects of current and
future therapeutic agents. Mol Psychiatry 17: 1206–1227.
Mohn AR, Gainetdinov RR, Caron MG, Koller BH (1999). Mice
with reduced NMDA receptor expression display behaviors
related to schizophrenia. Cell 98: 427–436.
Moy SS, Nadler JJ, Perez A, Barbaro RP, Johns JM, Magnuson TR
et al (2004). Sociability and preference for social novelty in five
inbred strains: an approach to assess autistic-like behavior
in mice. Genes Brain Behav 3: 287–302.
Nair SG, Gudelsky GA (2004). Activation of 5-HT2 receptors
enhances the release of acetylcholine in the prefrontal cortex and
hippocampus of the rat. Synapse 53: 202–207.
Navailles S, De Deurwaerdère P, Porras G, Spampinato U (2004).
In vivo evidence that 5-HT2C receptor antagonist but not agonist
modulates cocaine-induced dopamine outflow in the rat nucleus
accumbens and striatum. Neuropsychopharmacology 29: 319–326.
Nocjar C, Alex KD, Sonneborn A, Abbas AI, Roth BL, Pehek EA
(2015). Serotonin-2c and -2a receptor co-expression on cells in
the rat medial prefrontal cortex. Neuroscience 297: 22–37.
O'Neil PM, Smith SR, Weissman NJ, Fidler MC, Sanchez M,
Zhang J et al (2012). Randomized placebo-controlled clinical trial
of lorcaserin for weight loss in type 2 diabetes mellitus: the
BLOOM-DM study. Obesity (Silver Spring, MD) 20: 1426–1436.
O’Neil R (2010). Role of the 5HT2C receptor in regulation of
metabolism and mesolimbic dopamine. Vanderbilt Rev 2: 19–24.
Park SM, Chen M, Schmerberg C, Dulman R, Rodriguiz RM,
Caron MG et al (2016). Effects of β-arrestin-biased dopamine D2
receptor ligands on schizophrenia-like behavior in hypo-
glutamatergic mice. Neuropsychopharmacology 41: 704–715.
Porras G, Di Matteo V, Fracasso C, Lucas G, De Deurwaerdère P,
Caccia S et al (2002). 5-HT2A and 5-HT2C/2B receptor subtypes
modulate dopamine release induced in vivo by amphetamine and
morphine in both the rat nucleus accumbens and striatum.
Neuropsychopharmacology 26: 311–324.
Rosenzweig-Lipson S, Comery TA, Marquis KL, Gross J, Dunlop J
(2012). 5-HT2C agonists as therapeutics for the treatment of
schizophrenia. Handb Exp Pharmacol 213: 147–165.
Roth BL, Scheffler DJ, Kroeze WK (2004). Magic shotguns versus
magic bullets: selectively non-selective drugs for mood disorders
and schizophrenia. Nat Rev Drug Discov 3: 353–359.
Salamone JD, Correa M (2012). The mysterious motivational
functions of mesolimbic dopamine. Neuron 76: 270–285.
Salamone JD, Steinpreis RE, McCullough LD, Smith P, Grebel D,
Mahan K (1991). Haloperidol and nucleus accumbens dopamine
depletion suppress lever pressing for food but increase free food
consumption in a novel food choice procedure. Psychopharma-
cology 4: 515–521.
Schaefer GJ, Michael RP (1984). Drug interactions on spontaneous
locomotor activity in rats. Neuroleptics and amphetamine-
induced hyperactivity. Neuropharmacology 23: 909–914.
Seidman LJ, Lanca M, Kremen WS, Faraone SV, Tsuang MT (2003).
Organizational and visual memory deficits in schizophrenia and
bipolar psychoses using the Rey–Osterrieth complex figure:
effects of duration of illness. J Clin Exp Neuropsychol 25:
949–964.
Smith SR, Weissman NJ, Anderson CM, Sanchez M, Chuang E,
Stubbe S et al (2010). Behavioral modification and lorcaserin for
overweight and obesity management (BLOOM) Study Group.
Multicenter, placebo-controlled trial of lorcaserin for weight
management. N Engl J Med 363: 245–256.
Siuciak JA, Chapin DS, McCarthy SA, Guanowsky V, Brown J,
Chiang P et al (2007). CP-809,101, a selective 5-HT2C agonist,
shows activity in animal models of antipsychotic activity.
Neuropharmacology 52: 279–290.
Swartz MS, Perkins DO, Stroup TS, Davis SM, Capuano G,
Rosenheck RA et al (2007). CATIE investigators. Effects of
antipsychotic medications on psychosocial functioning in patients
with chronic schizophrenia: findings from the NIMH
CATIE study. Am J Psychiatry 164: 428–436.
Swerdlow NR, Shoemaker JM, Bongiovanni MJ, Neary AC, Tochen
LS, Saint Marie RL (2005). Reduced startle gating after D1
blockade: effects of concurrent D2 blockade. Pharmacol Biochem
Behav 82: 293–299.
Terranova JP, Chabot C, Barnouin MC, Perrault G, Depoortere R,
Griebel G et al (2005). SSR181507, a dopamine D2 receptor
antagonist and 5-HT1A receptor agonist, alleviates disturbances of
novelty discrimination in a social context in rats, a putative model
of selective attention deficit. Psychopharmacology (Berl) 181:
134–144.
van der Meulen JA, Bilbija L, Joosten RN, de Bruin JP, Feenstra MG
(2003). The NMDA-receptor antagonist MK-801 selectively
disrupts reversal learning in rats. Neuroreport 14: 2225–2228.
Weinstein JJ, Muhammad OC, Slifstein M, Kegles LS, Moore H,
Abi-Darham A (2017). Pathway-specific dopamine abnormalities
in schizophrenia. Biol Psychiat in press 11: 551–568.
Wigman JTW, van Nierop M, Vollebergh WAM, Lieb R,
Beesdo-Baum K, Wittchen H-U et al (2012). Evidence that
psychotic symptoms are prevalent in disorders of anxiety and
depression, impacting on illness onset, risk, and severity—
Implications for diagnosis and ultra-high risk research. Schizophr
Bull 38: 247–257.
Young JW, Markou A (2015). Translational rodent paradigms to
investigate neuromechanisms underlying behaviors relevant to
amotivation and altered reward processing in schizophrenia.
Schizophr Bull 41: 1024–1034.
Supplementary Information accompanies the paper on the Neuropsychopharmacology website (http://www.nature.com/npp)
